Browse > Article
http://dx.doi.org/10.5012/jkcs.2003.47.6.601

Surface Mmodification of Poly(DL-lactide-co-glycolide) Nanoparticle  

Oh, Yu-Mi (Advanced Materials Division, Korea Research Institute of Chemical Technology)
Jung, Taek-Kyu (Advanced Materials Division, Korea Research Institute of Chemical Technology)
Chi, Sang-Cheol (College of Pharmacy, SungKyunKwan University)
Shin, Byung-Cheol (Advanced Materials Division, Korea Research Institute of Chemical Technology)
Publication Information
Abstract
We studied on preparation of nanoparticles modified surface using biodegradable polymer, poly(DL-lactide-co-glycolide) (PLGA). Two kinds of PLGA nanoparticles were prepared by a spontaneous emulsification solvent diffusion (SESD) method using cetyltrimethylammonium chloride (CTAC) and tetradecyltrimethylammonium bromide (TTAB) as a cationic surfactant and polyethylene glycol-block-polypropylene glycol copolymer (Lutrol F68) as a nonionic surfactant. Model protein was coated on the surface of nanoparticles by the ionic complexation. The model protein was that influenza vaccine ($H_3N_2,\;H_1N_1$, B strain) labeled with NHS-fluorescein. The sizes of cationic nanoparticles were 140-160 nm and the surface charges were 50-60 mV. The sizes of nonionic nanoprticles were 80-90 nm and the surface charge was -10 mV. After coating vaccine on the surface of nanoparticles, the sizes of cationic nanoparticles were increased to 380-400 nm and the size of nonionic nanoparticles was not increased. The amount of coated vaccine on the cationic nanoparticles was 22.73 ${\mu}g$/mg.
Keywords
PLGA; Nanoparticle; Vaccine; Cationic Surfactant; Surface Modification;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Murakami, H.; Kobayashi, M.; Takeuchi, H.; Kawashima, Y. Int. J. Pharm. 1999, 187, 143.   DOI   ScienceOn
2 Hiraku, O.; Yoshiham, M. Biomaterials 1999, 20, 175.   DOI   ScienceOn
3 Park, S. J.; Kim, S. H.; Lee, I.R; Lee, H. H.; Hong, S. K. Polymer (Korea) 2002, 26(3), 326.
4 Murakami, H.; Kawashima, Y.; Niwa, T.; Hino, T.; Takeuchi, H.; Kobayashi, H. Int. J. Pharm. 1997, 149, 43.   DOI   ScienceOn
5 Couvreur, P.; Kante, B.; Roland, M.; Speiser P. J. Pharm. Sci. 1979, 68, 1521.   DOI
6 Couvreur, P.; Kante, H.; Lenaerts, V.; Scailteur V.; Roland, M.; Speiser P. J. Pharm. Sci. 1980, 69, 199.   DOI
7 Couvreur, P.; Kante, B.; Grislain, L.; Roland, M.; Speiser P. J. Pharm. Sci. 1982, 71, 790.   DOI
8 Allemann, E.; Gurny, R.; Doelker, E. Eur. J. Pharm. Biopharm. 1993, 39, 173.
9 Quintanar-Guerrero, D.; Allemann, E.; Fessi, H.; Doelker, E. Drug Dev. Ind. Pharm. 1998, 24, 1113.   DOI
10 Zimmer, A.; Kreuter, J. Adv. Drug Deliv. Rev. 1995, 16, 61.   DOI   ScienceOn
11 Peppas L. B. Int. J. Pharm. 1995, 116, 1.   DOI   ScienceOn
12 Leroux, J.-C.; Allemann, E.; De Jaeghere, F.; Doelker, E.; Gurny, R. J. Controlled Release 1996, 39, 339.   DOI   ScienceOn
13 Soppimath, K. S.; Aminabhavi, T. M.; Kulkami, A R.; Rudzinski, W. E. J. Controlled Release 2001, 70, 1.   DOI   ScienceOn
14 Labhasetwar, V.; Song, C.; Levy, R. J. Adv. Drug Deliv. Rev. 1997, 24, 63.   DOI   ScienceOn
15 Kreuter, J.; Speiser, P. J. Pharm. Sci. 1976, 65, 1624.   DOI
16 Govender, T.; Stolnik, S.; Garnett, M. C.; Illum, L.; Davis, S. S. J. Controlled Release 1999, 57, 171.   DOI   ScienceOn
17 O'Hagan, D. T. Adv. Drug Deliv. Rev. 1998, 34, 305.   DOI   ScienceOn
18 Michael, V.; O'Hagan, D. T. Adv. Drug Deliv. Rev. 2001, 51, 127.   DOI   ScienceOn
19 Brannon-Peppas, L. Int. J. Pharm. 1995, 116, 1.   DOI   ScienceOn
20 Vila, A.; Sanchez, A.; Tobio, M.; Evora, C., Soriano, I.; McCallion, O.; Alonso, M. J. Pharm. Res. 1998, 15, 270.   DOI   ScienceOn